Markets:

Overview

News

Currencies

International

Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

13.30 -0.02 (-0.15%)

Streaming Delayed Price Updated: 3:30 PM EST, Jan 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dr. Reddy's Laboratories Ltd Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Dr. Reddy's Laboratories Announces the Launch of Treprostinil Injection in the U.S.

April 21, 2023

From Dr. Reddy's Laboratories Ltd.

Via Business Wire

Why Aditxt Shares Are Surging Today ↗

April 20, 2023

Aditxt, Inc. (NASDAQ: ADTX) stock is surging Thursday as it expands its portfolio to include innovative therapies for infectious diseases.

Via Benzinga

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) Making Surprising Moves in Wednesday Session

April 12, 2023

Via Investor Brand Network

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) Sets New 52-Week High in Monday Session

April 10, 2023

Via Investor Brand Network

Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development

March 23, 2023

By David Willey, Benzinga

Via TheNewswire.com

Intercept Settles Ocaliva Litigation With Reddy's Lab ↗

August 17, 2022

Via Benzinga

India Based Pharma Companies In Race To Buy Athenex, Shares Surge ↗

August 05, 2022

Via Benzinga

Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development

March 23, 2023

Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development

Via News Direct

Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development ↗

March 22, 2023

Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India.

Via Benzinga

Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302

March 21, 2023

Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302

Via News Direct

Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302

March 21, 2023

By Kenneth Adams, Benzinga

Via TheNewswire.com

Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy's Laboratories To License And Commercialize COYA 302 ↗

March 20, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced a worldwide agreement with Dr. Reddy’s Laboratories Limited.

Via Benzinga

Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases

March 20, 2023

From Coya Therapeutics, Inc.

Via Business Wire

Dr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Generic Prescription Deal ↗

February 27, 2023

Via Benzinga

Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio

February 27, 2023

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Dr. Reddy’s included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global’s Sustainability Yearbook for the 3rd year

February 08, 2023

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

The 3 Most Undervalued Stocks in India for Your February Buy List ↗

January 31, 2023

These are a few of the top undervalued stocks in India, providing investors with exposure to strong growth outlooks in the coming years.

Via InvestorPlace

Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

January 27, 2023

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years ↗

January 25, 2023

Intercept entered a deal with Amneal, likely lining up a series of new settlements.

Via Investor's Business Daily

Dr. Reddy’s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe

January 20, 2023

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Journey Medical Touts Positive PK Data For Bacterial Infection Candidate ↗

December 20, 2022

Via Benzinga

Dr. Reddy’s Successfully Completes Phase 1 Study of DRL_TC, a Proposed Biosimilar of Tocilizumab

December 19, 2022

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug ↗

October 14, 2022

The U.S. Supreme Court rejected Novartis AG's (NYSE: NVS) effort to block the launch of generic versions of its multiple sclerosis drug Gilenya.

Via Benzinga

World Economic Forum Recognises Dr. Reddy’s Hyderabad Factory as Part of its Global Lighthouse Network

October 11, 2022

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity

September 07, 2022

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Is Sanofi A Buy, Despite Recent Stumbles?

August 19, 2022

Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions.

Via MarketBeat

Topics Intellectual Property

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗

August 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

August 05, 2022

Good morning! We're starting off the last day of trading this week with a breakdown of the biggest pre-market stock movers for Friday!

Via InvestorPlace

Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.

July 29, 2022

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market

July 27, 2022

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.